Deconstructing the neuropathic pain phenotype to reveal neural mechanisms
Three FDA-approved GLP-1 medications are eligible under the bridge program when used to reduce excess body weight and maintain weight reduction: Wegovy (semaglutide), available as a weekly injection or daily oral tablet, manufactured by Novo Nordisk Zepbound (tirzepatide), available in the KwikPen autoinjector format, manufactured by Eli Lilly Foundayo (orforglipron), the first non-peptide, small-molecule oral GLP-1 for weight loss, recently FDA-approved and manufactured by Eli Lilly Each of these medications works by mimicking the activity of glucagon-like peptide-1, a hormone that regulates appetite, fullness, and blood sugar
They can help produce biochemical energy from nutrients in the body's blood supply
Adems, los pacientes que combinan el tratamiento con modificaciones en la dieta y actividad fsica regular generalmente experimentan resultados ms rpidos y significativos, como recomiendan las guas de la ADA y AACE
Real-world data confirms trial results Clinical trials occur under controlled conditions